Breaking Finance News

Bioline RX Ltd (NASDAQ:BLRX) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Boasting a price of $0.87, Bioline RX Ltd (NASDAQ:BLRX) traded 0.96% higher on the day. With the last stock price close down 8.74% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Bioline RX Ltd has recorded a 50-day average of $1.08 and a two hundred day average of $0.97. Volume of trade was down over the average, with 125,334 shares of BLRX changing hands under the typical 573,959

Zacks Investment Research has downgraded Bioline RX Ltd (NASDAQ:BLRX) to Sell in a statement released on 06/20/2017.

On 5/29/2017, Zacks Investment Research released a statement for Bioline RX Ltd (NASDAQ:BLRX) bumped up the target price from $0.00 to $1.00 that suggested an upside of 0.18%.

Performance Chart

Bioline RX Ltd (NASDAQ:BLRX)

With a total market value of $0, Bioline RX Ltd has with a one year low of $0.80 and a one year high of $1.42 .

A total of 3 equity analysts have released a ratings update on BLRX. zero equity analysts rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $4.67.

Brief Synopsis About Bioline RX Ltd (NASDAQ:BLRX)

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *